Summit Therapeutics' drug Ivonescimab posted positive results in not one but two phase 3 trials during 2024. It also received "fast track" status from the FDA. Despite its massive 2024 gains, analysts ...
Clinical Trial Collaboration with Pfizer Evaluating Ivonescimab in Combination with Several Vedotin ADCs in Unique Solid Tumor Settings; Clinical Trials Expected to Start Mid-2025 Enrollment Completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results